Elahere Injection, Solution
Product Images NDC 72903-853

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Elahere (NDC 72903-853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Immunogen, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Elahere 01)

Chemical structure of Mirvetuximab Soravtansine shown as a complex molecular formula diagram with various functional groups and molecular bindings, illustrating the detailed arrangement of atoms in the active ingredient of the drug ELAHERE injection solution.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Packaging label for ELAHERE 100 mg/20 mL (5 mg/mL) injection, an intravenous solution of mirvetuximab soravtansine-gynx by ImmunoGen, Inc. The label includes dosage information, storage instructions (store refrigerated at 2°C to 8°C), a barcode, and warnings such as 'Hazardous Drug.' It specifies single-dose vial use and dilution instructions for intravenous infusion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.